Ascendis Pharma A/S (ASND) 16 Feb 232022 Q4 Earnings call transcript

Good day, and thank you for standing by. Welcome to the Ascendis Pharma Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session [Operator Instructions]. Please be advised that, today's conference is being recorded.

to today, call of Tim like your to Investor now for speaker Lee, would turn over the now Relations. I Senior Director ahead, go the is Please floor yours.

full thank Tim I'm Senior Director at for Thank conference Relations Lee, you Investor Pharma. operator, financial results and joining you, our Ascendis year of XXXX call. everyone

Vice Clinical Joining me Officer; is Officer; Smith, Oncology; Vice Executive today Stina Scott President, Kelly, Chief Dr. President Senior Financial of Mikkelsen, Commercial Head on Jan the President, Singel, Joe and of Executive President Development Endocrinology. call Executive and Head and Vice Chief U.S.

limited Before SKYTROFA of of regarding Securities US we a launch regarding statements biopharma TransCon this clinical our statements new goals statements pipeline are that leading like approval timing statements Reform statements continued expected such potential US our commercialization for our pipeline of market to for areas of into the timing in Litigation TransCon filings, approval of statements regarding candidates, provided under regarding our strategic clinical our include, remind expectations TransCon regarding ability forward-looking create conference to results, intended Europe, planned the not and candidates you and plans, harbor their of therapeutic the be covered Act. the regarding of in market, progress, Examples progress our to the regulatory begin, the statements the year, continued of that timing EU I may statements TransCon expansion company. would size are the statements market, contain PTH global our our the regarding including market expected PTH Private PTH, and hGH respect call with but pipeline, commercialization product our sustainable regarding development next and the to, the will safe to of US and by

today. able should not information our intentions, those in Actual you on to on statements, goals, forward-looking may differ out our that our results and achieve is the based could place us or be these materially from to available forward-looking and statements. undue our events our expectations we reliance not projections disclosed in are statements plans, carry These And statements.

Our not licensing acquisitions, or by circumstances the change impact required obligation of potential enter forward-looking that law. statements into mergers, statements these agreements, or to assume do We we joint as reflect any terminate. investments may ventures update dispositions, no except as

materially, statements that most additional the is concerning section which differ see our actual sections today, February release the XX-F, of XX, to and XXXX. For information in forward-looking form report factors on today's results please filed factor annual press our could being cause risk

or brand for Hormone the treatment one have kilograms the pediatric SKYTROFA hormone. growth and failure TransCon patients older year is FDA of hGH under name Growth to Human in approved of endogenous TransCon the inadequate at secretion US growth by weighing the XX.X due least

referring growth to and failure hormone. due to as TransCon product refer for SKYTROFA three the In children addition, under adolescents marketing developed has injection onceweekly XX insufficient secretion with we general, growth Commission TransCon In to years of we the endogenous hGH for Ascendis unless a treatment granted aged authorization the growth European a this name are subcutaneous is in the Pharma to of hormone, product to and

of or the note context jurisdictions please Union. United commercial investigational use. not and the Otherwise, candidates our product such States as are approved particular European the a that are

product promotional. conference call product viewed regarding not the on candidates of effectiveness shall and have any made the reviewed be statements approved safety the or candidates been agency. as None products, by our regulatory investigational As of the

today, and the we'll updates. further provide results financial On XXXX business call full year our we'll discuss

turn now then open will questions. Chief I'll to Jan call Executive the Officer. remarks, some Following President we Jan? the for over prepared and Mikkelsen, up call

Thank much. so you

built unique development higher multiple enabled therapeutic differentiated candidates technology highly technology us product of conventional with areas. and across the Combining development. of innovation [indiscernible] product develop candidates to seen Ascendis which on with create likelihood success enables a platform, has our than TransCon product drug is the TransCon with

One criteria key tolerability pillars on Safety, selection the drug product development. each of convenience. four best-in-class fulfill is of of our to efficacy, potential key and

for adult entering profitable, company end Commission all pipelines from must opportunity, approach by greater In building billion have QX, single revenue candidate and XXXX have to addition, product the PDUFA or TransCon we through product date additional April $X for representing potential robust an while value past term expected launch a product this global $X by our one or a during as expected our TransCon Vision stakeholders. we we with greater therapeutic an QX rare values decision and of a hyperparathyroidism indication fulfilling are indication. With of passion, of creating long launch. regulatory expected pipeline, our sustainable, and PTH European taking planned demonstrated approvals than of opportunity in disease ability years, to concept patients, of XxX PTH to every patient and continuously a advanced potential our leading each approval well. is billion. with build biopharma a product the achieve along [terming] goal candidates out have science second endocrinology With with US and new year, our XXth two as This

achondroplasia. children this our Last reported ever Turning give we diagnosed product candidate results approval by endocrinology rare in Phase third November, have first controlled Vision double to our randomized, target from TransCon from XX XXXX as disease -- with confidence may trial blind, placebo first first its the that XxX. data These months CNP. me X in

XxX covenant expansion. its Vision Another geographic of label and

programs reads. organization, TransCon build like expansion label review commercial newly with I details for additional We additional next our approved global and major preparing this continue to value which our our studies through of from expanded year. if clinical the existing With programs. and of Starting for European across pipeline, momentum year great PTH launch to SKYTROFA would this Germany our is in

hormone. growth to Turning

it line plan Phase X rare hormone more year, for first characteristic adult Analysis only deficiency serious report we deserved, of results hormone we in is exceed the growth once treatment dyslipidemia, the body times daily growth healthcare be hormone. global non-growth dis impaired top by tolerability quarter is hormone X its of the adult growth abnormal of product to US, a hormone the cost population. hormone weekly life. consequence hormone unmodified hormone somatropin, SKYTROFA than insulin expect TransCon a shown TransCon product that or to safety, indication strengths. disease second Because deficient the and success analyzed the our because the Meanwhile, endocrine growth has this growth meet of growth During potential in foresiGHt mean efficacy composition, commercial experienced growth trial of Adult resistance from in to growth our it unique deficiency, of hormone. and is adult deficiency result quality releasing fourth

towards we and hormone fourth after. million, providing quarter progress US SKYTROFA growth and expansion pre-announced growth during our With fundament As XXXX a for revenue JPMorgan, XXXX strong label in planned to €XX.X track on leading US, increasing launch total by markets site. we growth product market the -- commercial build in can we the believe into to SKYTROFA value be outside track in the

other US seeing hormone market are have consolidation we begin daily of market. manufacturers the growth we as exit the As to the predicted,

Excitement to stakeholders with build upcoming Turning potential hypopara date XXth. among PTH. TransCon for ahead treatment the continues of adult this to April around of patient PDUFA

health physician serious payor quality and Our to issue working awareness life of expanded this causes. deepen teams are and hired, that hypopara trained and of

and to related We negative are of on we to have patients disease encouraged more awareness already multi-organ made more of than effect quality physician impact life. their in disease about this interest X,XXX by call the learning its and

reimbursement after commercial manufacturing to premium team, are launch the soon TransCon approval. as teams market and in Our ready medical possible affairs, US as PTH our

second we disease product launching rare Importantly, infrastructure commercial with TransCon success our same CMP. SKYTROFA. proven to back with the that PTH, has Coming its are endocrinology

controlled X four As safety, profile and key robust TransCon to Growth level. derisk and and This only XX. CNP, X clear superiority does tolerability the confirm pillars, Phase TransCon randomized ran TransCon can trial TransCon demonstrating efficacy, XX PTH, success two that Hormone ACcomplisH in be with placebo We months to as we trial. the a we at target pivotal placebo the done with aged with saw all over or a trial mimic children it primary did CNP’s robust in Phase endpoint convenience, trial

label patients in extension today. In started addition, dose we open the response. All saw trial clear this XX who remain

including running Phase our To ApproaCH positive we comorbidities, confirm trial. on results, are these extend related treatment achondroplasia observed and Xb effect

the in expect As quarter. aware XX ApproaCH very experienced results target trial, enrollment around patients of X I’m of I the high our in interest we Phase where complete to and investigator next

to During labeling collaborate alone. end expect our best broad achieve FDA, labeling rather treatment a linear Phase of with how upcoming we to than meeting X a on

to oncology. Shifting

We development immuno are β/γ. TransCon our agonist IL-X novel progressing and the oncology programs, with TransCon two of TLRX/X

proof these starting programs, including our we therapies, Phase in concept of With with TransCon Clinical seven different top by results year of start two to four efficacy X tumor types, this indications other. XXXX. candidates nine positioned different are expected oncology specific clinical clinical iteration in combination two each are line with product combining

in initiate In cancer. trial β/γ addition, head IL-X Phase TransCon therapy and the would TLRX combination this using neck we XXX βelieγe randomized X year agonist and

X our in clinical we one products are of two with As we endocrinology years. tumor Phase proof demonstrated or concept for in successfully multiple oncology solid building types a the next our programs,

power always product efficacy, positioned which robust for benefit approach, see, one to Vision safety, future our the building a not the have compromise. we or sustainability, innovation Ascendis development extremely to the meet you confirms commercial product two As This XxX. value will stakeholders. [indiscernible] increase on expanded trial can successes, including and on and launch [indiscernible] trial and and successful product best-in-class indication and in convenience, track has exceed potentially patients likelihood platform new product long on successful every to our candidates. remains [receiving] of profile outlined pipeline design, clinical goals term years, pillars of on areas to four and further in confidence all of or clinical Ascendis build key we our This To tolerability technology our focus will

will a call for review to Scott questions. now for up we turn over open the financial I before

of of to Vision Jan’s excited on indications continued two years. with products To are realization the flow follow new we XxX to every see one and a additional comments,

year, we our CNP launch SKYTROFA in deficiency PTH adult in TransCon For and this early TransCon With for of this first in Germany and are PTH value XXXX. I proven R&D In the this European results example, hormone long as XXXX. expect beyond US Jan to growth we horizon, we a for in of noted, the points. TransCon to through on followed launch by term our the cadence expect Ascendis SKYTROFA on way, in and few touch continue sustainable and country capabilities. launches quickly development achondroplasia stakeholders will approvals creating

For details please full XXXX is financial to results, refer our our on today. Form filed year XX-F, being further which

quarter announced These million. previously last €XX.X to projected for in revenue results we which laid that exceeded As January, the of May, Jan XXXX out grew SKYTROFA €XX algorithme early US million. fourth the

€XX.X operating For was total XXXX. million as from revenue loss including year fourth SKYTROFA, third sequentially €XX.X for the X% to supply about of well million €XXX.X as clinical million of to full growth With €XXX.X in licensed quarter our XXXX, the profitable primarily the overall VISEN of quarter services provided third parties Pharmaceuticals. million, grew SKYTROFA and revenue

equivalents Finally, we €XXX with securities and cash, cash million. marketable ended XXXX totaling

as €XX.X JPMorgan foundation the million Looking for SKYTROFA provides XXXX. fourth forward, of quarter revenue described a annualizing conference, Jan at

would In growth. even many addition, at to as as provide patients we year this add we in least did greater which XXXX, reimbursed expect

at result, million. XXXX time, estimate are track a Ascendis compiled to the exceed revenue believe this of As we consensus on SKYTROFA current we for €XX

Switching TransCon PTH. to

to If expect XXXX Our PDUFA the shipping end the by corporate of product begin milestones. this reminder selected second April quarter. year. on is date XXth quick approved, key A we

global trial Europe, the TransCon QX. in SKYTROFA for QX. line QX, planning by second commission the For in Phase we also US QX. PTH, And of with X the decision Germany PDUFA hormone data TransCon and growth expect expect Growth end in indication in plan date of European to approval in we April our in deficiency, we FDA launch top foresiGHt by to are and mentioned, XX the starting launch Hormone, the report we as adult from

the recommended β/γ with β/γ X monotherapy quarter, combo ApproaCH Xb inhibitor TransCon in enrollment X QX. to and IL- we and line recommended track in TransCon to dose trial For X Phase X area, are oncology dose our cohorts complete we to the TransCon Phase Phase CNP, for dose therapeutic IL- expect later for on checkpoint escalation report QX. achondroplasia in top declare therapy declare of Within the this results from

and Finally, as enabled us our have you our continued of to date, see systems end optimization reporting accelerate processes finance with year reporting. to

ready operator, that, are to we With take now questions.

Thank you.

question be Our coming for today from first will of JPMorgan. Fye

how you And where Can think based the to for consensus SKYTROFA comment year? consensus it, latest is with comfort actually that level analyst on this about your we're at comments figure the numbers? of on for Thanks this year. PTH compilation while sales on your TransCon estimates

Jess, TransCon PTH? reflecting or are you into SKYTROFA

For PTH.

consensus I don't actually think collected at have I number for that we the information. PTH. not looked have

done give SKYTROFA. address algorithme where really We that can So I an expectation feel we from the our have that. can don't mainly think reflect address confident we can places to we as

tell many you of end? patient Can look to I us update giving should that Okay, previously I'm extension were the for Phase then. there And CNP? you prescriptions can quarter. you else SKYTROFA were X TransCon how when us for as new for think from quarter we by ask also next going the cumulative something tell your

we increased is trend number basically the US reimbursed, here is you also revenue how at why SKYTROFA, have SKYTROFA that fourth I month by we it’s have to a multiply we When time, XXXX. in looking patients What million look the got about related strong of and that, take quarter, Scott the will we're on XXXX. we month, Let's back on of of you are same seeing on really and start you €XX in we €XX.X stay that acceleration to was just to And that. lot go expect in the important we this seen retention. 'XX to in to forecasting back the Jesse, very an see have we can also on it good the that calculating, because new in This reason. the seen of SKYTROFA. When basically come patients, And want if the with and of new because number million. of continued X,

to We're that reimbursed actually per of number in is on to we month out the will patients more see exceed 'XX. feeling actually that the today saw confident SKYTROFA. really, expect that we patients So consensus we really, new really related street

starting XX starting is get new we're you one product data. we're our month, number to you the need And what to a the increase to the see six hormone. not SKYTROFA. that of knowledge we element basic that is providing see, so compared The of product growth differentiated -- how really strength in daily of about monthly months experience have reimbursed It's patients is highly physician to months, really something seeing this really in

market our three the really now. is see daily we that The the saw other hormone we consolidation data that of where market point in growth is consolidation after for growth started about the hormone of the daily Phase ago years that X kicking

the a daily players, is have which from the hormone switch away of same growth that major, some six major product. all So

we this the Jess, product you why grow how is really we to specify you growth what future. CNP. the though. wanted near you exactly a feel know, market most SKYTROFA would related in into about confident So valued Related hormone to the CNP, in had question can to that

that? been kind that about time out talked point, should going in the patients up plan to Is we're the the a maybe point. data certain that when a high Well, proportion and past, and you we all I on update for of of update expect to patients one I think there that time that had got to think velocity to

out trial endpoint give extremely, why think planning much had we lot on CNP because the is TransCon really this data. this the we now seek are the therefore and the are a to molecule starting effects better and growth. how and not is just in what XXX% this reflecting it the group, all only can of still exposure And of extremely struggling treatment, to why find get other to we the are you of agencies analyzing comorbidity is our really where data a how secondary because we Linear important growth. to ACcomplisH not a comorbidities unique And for and continuous this we TransCon product we see why issue that's we data this regulatory really discussing that. CNP, disease. this of really And is got are biggest we is have believe growth And is understanding not Pharma’s changing manner. you the addressing other they're linear Ascendis this related linear CNP for to things that continuous patient much, we staying out have extremely give this of I'm is Yes, effect they

Our Bank next Instructions]. of Ahmad from question will be [Operator of coming America

to As And with the you've HPT, on just far? can Program you following Early then update, the patients many if enrolled of an in do program how give it many in PDUFA by of time will the sense how the be a already, Access and relates haven't enrolled patients launch? have us you you that so

got is get to that expected [indiscernible] our program approval give we the all, extremely is with treatment an the and progressing extreme the to the start first are pleased under patients regulatory think program and an also how of we interaction, get opportunity EAP -- that I approval. with we before

with continue we approval we come how process, in that, the patients the this have is the really system. also trial, we starting entire executing number patients. and what we are will of will on And to We explain when

expect early of just that to source be to patients convert Would commercial? an Maybe you a to then. follow-up

program. we the a think key element EAP are addressing just in I

group was patient treatment acting We patient we’re loss] but that never PTH The our experienced program a a exactly to coming are could could addressing. Phase be call It and treatment. really [time the what we that from where they’re [indiscernible], exposed with program, [indiscernible], be X basically recruited vast we regime, were already that PTH had PTH could Phase our patient population X someone been or the to what else, it be addressing treatment. short it

that differentiation So I groups. a don't really, see really patient is between two these --

of same the patient they groups I think unmet have both the high need, same treatment. medical benefit PTH have the

any kind related see don't I our two So difference in programs. be groups firestarter these to of between

from be question Bank Our of to Tazeen next coming will Ahmad of America.

just next she the question, think so I go asked to the I'd one.

The Lebowitz next question is of from Citi. David coming

experience. the know As I label could be going really NATPARA but a approaching, is ultimately you a PDUFA date insight the seek that considered as didn't us an presence might give into replacement, an and NATPARA was any for osteosarcoma more has the blackbox of you like? adjunct, hormone look have you to what osteosarcoma,

So blackbox to be could hear Just removed? that curious your be thoughts.

we of seven biology think the days XX a look we a hours, PTH the on stable providing I of design physiological and product week. when are level TransCon PTH,

the you profile of acting group will hyperphysiological in that that we make and complete the effect rat And to provide acting why providing in be from will expect animal basically our short are model. animal is not a because we providing can we or perspective same, and discussion the also the not class anabolic we trial same are osteosarcoma been labeling, the We can we carcinogenic any have product concentration in short that with that labels PTHs. trial, got to of PTH to any not coming model see, that a waiver associated specific got that than have different a seen indication PTH

our warning. REMS expect best discussions, to or don't don't today we we So knowledge any program blackbox expect any in our and

adjunct. right. we your profile that to So was first designed really replacement that you're question. That’s of was also active quite just reflecting trial prove vitamin an the And only reflecting TransCon XXX% are multivitamin to in from successful D hormone PTH need that to why to really How and was be product a [indiscernible]. a need you clinical stop take supplements from calcium normal instead you

product are profile. we really complete So addressing different a

next our Cantor. question of Li from Watsek is And coming

for of thoughts share then physicians? access? if feedback from maybe that And payors maybe received PTH, approach about guess talk might TransCon your latest I can you on latest just market sales and pricing how wondering some the you and your team

How benefit is in the which awareness really And the what are And symptoms, after this life, building missing a that the When happening is we the Everyone much out first our come disease, with physiological go I I term what seven hours, risk. of long for And XX physicians, I that we measures long everyone up short been in much, we’re US. term. serious address different approval, the the also a but the both of hypopara both with calcium telling is our today of week. believe a not think here disease, about patients, have is when indication, more the level term established can urinary recognize seeing the about a of of where and a benefit that about with understand we like kind term awareness latest. how of being short quality disease. explain infrastructure disease this all think about an and and this days part awareness of is it the replacing can big

TransCon right. unmet I we enough we did highly SKYTROFA believes for products. medical differentiated, product, take can and our of real PTH. we really, cake, with class to address you really a is need is really a we physician, it's real products, to the with we product that best What to and share no them is for want are unmet payor, We And us a everyone always do because responsible product. believe that the premier a each we really, in that our loser. And develop where pricing so medical with is real situation real that have winner, for everyone be and need need then a patient, is medical this everyone, the where really need. the We both guidance with a we So addressing see the feel addressing win develop society if that one with unmet

Our is Paul of from next Choi Goldman. question coming

you I market might the you're there are to want SKYTROFA using you're SKYTROFA. currently that that would on as think for US learnings changes be would access PTH any on to in I ask, infrastructure applicable, you terms And what you to have share follow-up. either make the -- your the thoughts guess, that or and/or that from SKYTROFA? given compared in then I using same of your contracting I approaching guess payor question a a pipeline launch

utilizing are IT launch dedicated for and two product. same necessary dedicated systems, different the Sure, where commercial you all know to But to infrastructure. all to a infrastructure, a you there's huge different the out force, product be first launch have the We products. go establish have we really difference sales to is that the we the necessary people teams

successful commercial stage that US. a at coming We built launch and in an and the other from status, where the from risk Princeton people here in already we big have infrastructure form now. We Joe

we’re are unmet that huge it’s whereas medical a call alternative an infrastructure product, basically believe, is really already what I we So PTH proven TransCon what capability treatment. I with has into that doing placing no need addressing

success. huge fundamental a is a this -- think I

terms children our you're program, And in Thank on pursue, it then and [erbitux], little you a be specify positive of could color And the in planning that are a being neck baseline also that'd to the it you taking terms you is the maybe or in the head you follow-up, just that is XX of then plan your ApproaCH patient add and pipeline. trial? post for PD-X Do HPV enrolled publish as oncology just that, if post characteristics great? population to for questions. the can

on will think or take number take I one can two, [Multiple Speakers]. you Stina

me do demographic one, that's very really not I the and from accomplish the all have Let in a if our trial, the it. are because into very, it’s published actually that we think because interesting know population number a words I demographic take XX the addressing, have been patient the question still question,

bit say, high it’s question, irrelevant velocity all prescreening, you it, is hey, for can So cannot they because deceleration [indiscernible] two we why clinical the look velocity. the that have the somewhat because place velocity five, which four and between of you use and little XX% analyze nearly collected data totally I did then have channel years, you high normal with trial, high the with first -- the that not the in been analyze you and heavily because velocity. come built a puzzling high efficacy analyze before go of out/ of you And into have analyze

already two. and any you you drug achondroplasia So take if kind to nonsense interpolating it’s in meaningful data. the up what velocity specific high they're a matching, are efficiency I that reflecting do group, you’re the any This months it's high compare and trial, just into and placebo This group. go is XX of you obvious not value reflecting the compare this and group, scientific at start collected that my and look misleading XXX%. then six a you in nearly this to to movement and of value Stina? velocity and then in also do, to think is six have basic analyze a they like But on in not why placebo X the development, [indiscernible] you XXX take placebo into before from scientific can can the a element go you our because solid only have -- group key the is why and making patient compare is the analyze dosing take high or the like placebo matching

different proof types. In oncology, we efficacy concept for tumor are of in seven evaluating

right, You're do cancer. neck priority head have our one areas is and we of

βelieγe-IT-XXX a in be randomized chemotherapy expansion advanced as or more We the IL-βelieγe And metastatic the the than in study in containing patients dose cohort evaluating line regimen Phase metastatic in study, first cancer have line and and will those neck setting. will be no setting. study, of X single arm are the one second neoadjuvant will head -- had

So these of get our treatment look they systemic we're for of are before pathologic setting looking proof concept get endpoint will to in surgery primary evidence they before surgery, a response as and non-metastatic patients efficacy. at

Our next Fargo. from Archila question is coming Wells of Derek

to So Jan, I just were I from for you I PTH. ones you saying just TransCon in discussions quick caught that really thought two labeling wanted confirm, us.

And first year, again, that. we I just that see, I updates additional So half to half ACcomplisH, this wanted should is we guess, year? of when something confirm this expect also, from then of should second

I for through go expected approval me, months expected two before process, months three four before date an need an of approval is plan you [this [indiscernible] process, think, When [indiscernible] happen] months that. an to approval before sort

to we have And date before PDUFA now. anyone if process, been an I and XX so the weeks somewhere had approval think

If high. discussion, is you're at of risk the not started getting have labeled not approval

of believe will are we that’s happen extremely So how the happening. tracking be approval really therefore, progressing I out not needs it worried this going a is process, is I way time, what on. and everything track what to are find on by we that expected to is in

give now. cannot confident PTH why before be all because so are I anything approved. in that we remember yes, is a I I that milestones you seen I months feel And our And and I'm three that not a discussion, have expected TransCon belief approval. really at believe corporate that not this that an is product should least labeling that isn’t me

believe to because we them. an is tribe. QX many bit ACcomplisH update, that, will you out give a of the will come little that that in that's for related I But Sorry that from XX patients again, too

half second So it will be this the of year. in

coming The from Evercore. of next Schimmer question is Josh

little market? what you're have there a realize reported that the First of hormone outfall elaborate seeing Could it been the didn't in daily withdrawals. on growth options I SKYTROFA. but from withdrawn shortages, know you further some terms reflected on

impact So who a expect to anticipate well growth iun then you others have week this drawing the do as you option a once market and Novo And follow? year? the seen this of later do potentially launching Nordisk hormone you how

daily it’ll [example]. the be final -- daily potential really, believe call because I I or hormone, where segment, if biosimilar players, really their [indiscernible] got providing first is of it is Let and there, with textbook market Sandoz entered version my on that my it. but segment Sandoz really in had it's on start studies among a growth Teva the and first, that market daily exactly a and textbook same entity, Growth bioequivalent the was six project, the them amount have And the all treatment. growth what me I I same

bit rebate in this change can devices like different between other that back that. you and that product little was was and that things dependent like the other forth formulation, So in a different on things and

-- years So what player started four saw already for big we saw of some came some that our when to they about X many three, that treatment out the really Phase we we into data, reconsider with which to coming how that's what superior be to will stages this call and highly daily when will played market segment. be -- segment. the way And be compared different

forms, I sales their company's call. the of three saw removing already we time, basic as step this one, is that At

remove Your force. sales

providing that which can four them three where have The are one you think product, many have patients happen their you no you products, manufacturing, in take I [indiscernible], and the the next multiple growth when a over. could [established] and other is already and in the that in consolidation patient is are What of a then setting where growth hormone in two now that new are showed audience, then go presentation of really one multiple up I daily to believe second happen like none position take you providing or the done place, And they change you're your you of patient on it for of remove the that stop final And normal now. because stage, the because us up it hormone. you them. you basically hope look

accelerating sure, at same for or it, of experience that us, So we the on shortage in is see the for I you US. benefit, both benefit great accept differentiate patient time how thing people having treatment. growth because clinical the see where a need something of get be treatment hormone to it's really that actually the And one the a year

to thing, we this going we’re and think into patients really, avoid can for is shortest they treatment this effect. of us as many, really great really, a And sure many see as really a benefit. I hopeful help the So

question? second Your

given TransCon the breakthrough your for you’d view of was going I designation? ask differentiation considered of to if Actually, CNP, whether, filing

Yes.

endocrine same First of all, of daily hormone were potential, you entrant growth question acting, They're are action. one the you match all to I daily it you to molecule. endocrine setting mode profile. profile, the that complete all related not in the same benefit, treatment, linear composition, because acting see, long same lipid hormone improved of where Josh, about the reflecting When both of the the everything product. version get go we clinical -- long When them metabolic you benefit comes only from different have also also identical, paradigm the but the it shift, effect time shift, periodic the benefit the because all unmodified [indiscernible], have an growth cognitive changing over Novo other of really the paradigm the providing the only somatrope associated on and that Nordisk growth where I look like the call body

hormone hormone. also in the is as why at the half daily one believe this unmodified potential growth look Nordisk adult showed least daily deficiency, Novo of somatrope we is body hormone. get growth only And potential on at this our So it's less Phase with trial. X there's we to where can X as to our but they where Phase because us long showed potential basic two for improvement that any good will we stake other be in believe not now growth [indiscernible] the basic composition acting important

our that so all believe we is hormone that both differentiated regimes. growth acting product treatment to always benefit other hormone we to other clinical compared growth provide So long daily highly the and profile always us will

next coming of be Gershell Leland will Our Oppenheimer. from question

earlier on REMS But monitoring label. expect or on know the product? from the warning responded for you you a Two don't PTH requirements Jan, patients I could with me. that had blackbox you comment on any potential

clarify your question, Could mean exactly? you you do what

other patients serum in monitored whatnot? to for calcium, biomarkers words, Well, be need if bone

over to be really, because will after that in will stages. dose, in the When current quite I patient what we monitored manner. in when see stability part you over it where want to the monitoring, a they you That of is be are really of which more beta pretend same to be I more different we I in from will than stable, least perspective will metabolic two where think sure therapy calcium transition stabilize you have it. the kind will you the for calcium at provide stability we believe or believe group because see say you that they and a a calcium setup PTH, one from for be potentially of see TransCon to call are right see starting monitoring the we conventional you often. year coming PTH this hemostasis to I on call, patient list, being need And system really, an where will the what an stabilized, question patient basic

basically do bone markers. for of seen over more in I group also believe both something clinical density What every your typically we this that that is we will where way. now in four seeing patient and I are bone years, more element is includes patient more think typically this where our not that like is including three, and study analyze and [indiscernible] for have you any is parameter, normalization and

be I will not expect So monitoring. a standard will part of it that

mentioned second are from could primary that by and type there not important, type important respect seen for that benefits to with me very be replacement velocity. achondroplasia. would provide. a many sort Obviously, other community? earlier, had you benefits as But endpoint captured question to inform most about endpoint as Could us which regulatory And the purposes, is it's CNP primary but the of you data just [achondro] of maybe by the other as

why and feeling, a this reported we that all growth, with think patient really achondroplasia to SKYTROFA is to they're them that you reported but developing seeing see developing provide an I We then [Technical treatment from measuring where patient because addressing benefit. is TransCon an I we is and are specific it Yes, And outcome also combine sure we on can it that from CNP. then high linear the Difficulty]. we're we specific being trying addressing nearly coming to measuring decide growth kind frequent of you -- they're This ensuring how high, are developing can can to underlying have. clinical are what the comorbidities. a you is really and want benefits when high, achondroplasia I linear will comorbidities is have from huge will expect comorbidities concept, catch the specific the But we really we what of

will see how other that clear not One lot normal of function it's the for physical the things massive see just to receive normal work, change, that Difficulty] capture things that. to basically related like the operation do is do of the we and and this balance, time, [Technical us, not way in is to [Technical We elements sectors, same Difficulty]. beta the patients all like [Technical Difficulty] will we other like putting. like At we And those achondroplasia things other capture. -- try specific element

is coming question from Argyrides Andreas next from Our Wedbush.

give opportunity And are PTH. you're the this how for thinking When launching PTH, I on thinking then you end for launch? thinking compared NATPARA can -- So about off coming us you is insights some how -- to about the informing opportunity NATPARA a about it the expectations follow market 'XX, then have of of at when launch? maybe you're And the up? your the the

in clinical have labeling, different complete comaring different any to I'm will complete different NATPARA. benefit. PTH TransCon have way have clinical outcomes, It not complete

of different life. complete impact on quality just So

on not benchmark So using came was anything. a as It out with benefit on of product it what came is on XX product any that comparing we’re not addressing. calcium, life, the that. was underlying not not I'm quality product benefit showing There that disease. as seeing a a a that this out not I'm adjunct, a that not an urinary addressing really hour labeling out was came

me. you So for completely -- don't use that it's I any can also benchmark, meaningless

going in patients, I Europe opportunity were still market, there well, the or no adopters? approved to on had on mostly some they there longer. Are early guess that access product be no as it it to maybe were those the there's

has -- or like not. short But exposed think been on actually see Yes, is other injection before. acting to that. the where exactly PTH the that acting that somebody's patient used treatment. independent daily is elements to huge background exposed benefit being that and I is PTH is this address are short Yes, we as They to of

understanding PTH So patient on treatment I on PTH. I acting patient have less a PTH The come acting you to acting short understanding short a a big about there common if injection, more have as it’s a don't daily believe groups. that to seen that been been barrier TransCon have never perhaps PTH more get the any do believe for that don't common happen. on to of is But that to or group what for short of procedure need have they the a has need from get

can know covered you just already. you've then I one don't quick elaborate and a And this SKYTROFA, if maybe on and

switch hormone? growth. Sorry, that's growth me. for And if driving from you Thanks, dynamics did daily you I if launch seeing are it. and rates that can it the on higher guys. you Are But elaborate missed

the We we’re treatment. overall patient But rate switch everywhere. daily growth seeing coming but goes hormone, of from up a also only an the increased higher number see new number on

really, are it's height less, improving all the time. them up to not both of really likely one getting So new a

next Cowen. question from Werber coming of is And our Yaron

of give that negotiate discounting shouldn't Jan, it program, approved, a second Does secondly, within isn't to your kind second placement product you'll Obviously, point. a with be sort to interrelated With PTH the the I've need better really thoughts contract then formulary, coming coverage. have two will maybe there Do And there? you questions bag. talk on very for competitor. PBMs to you get now on about of contract more or soon, more at that you a leverage endocrine high SKYTROFA? for

in provided US. benefit We we high will system market patient, in strategy. we us when providing addressing the how Compared the I we the basically continue to we SKYTROFA, pretty is differentiation, actually in really can are and information, this in reimbursement a look about the US rebated same are at strength the But and that are is name being really product, how we satisfied you for thing, our We are to lead we pathway, of our product, because know are a the give strategy to assess because I versus product. US always do the your be, generate to a comments position will you billion and that the the follow revenue coverage. in don't multiple basically will without this can think such into rebate. And society feel we the way physician a market with really of believe the an our provide highly products

having that is of strengths product. a differentiated I the highly think

today. for the all call. the Thank for joining have you. time you conference we that That's Thank

evening. a good have all You

you. Thank

much. See so Thank you you.